SARS CoV-2 IgG S1
HEK293 Cells.
Description
Recombinant Anti Human SARS CoV-2 IgG1 Kappa Spike S1 is a recombinant monoclonal antibody derived from HEL293 cells which recognizes the SARS-CoV and SARS-CoV-2 Spike glycoprotein. CoV-2 IgG S1 Antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity at amino acids 318-510 (RBD, Receptor Binding Domain) in the S1 subunit of the Spike protein.
Product Specs
For optimal storage, maintain at 4°C for up to 2 weeks. For extended storage periods, store at -20°C.
HEK293 Cells.
Protein A affinity purified.
The ELISA Plate was coated with the target proteins at 5 µg/ml. Primary antibodies were titrated on a 3-fold serial dilution starting at 125 ng/ml, CoV-2 IgG S1 antibody recognises SARS-CoV-2 spike protein subunit 1 (aa 1-674), or 41.6 ng/ml CoV-2 IgG S1 antibody recognised spike protein from SARS-CoV (subunit 1, aa 1-666) and SARS-CoV-2 (subunit 1, aa 1-674). Secondary antibody anti-human IgG conjugated to HRP used in the assay, at 1:4000 concentration.
The native monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV
Product Science Overview
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to an unprecedented global health crisis. One of the critical components in the fight against this virus is the development of antibodies that can neutralize its effects. Among these, the Recombinant Anti-Human SARS-CoV-2 IgG Spike S1, Monoclonal antibody has emerged as a significant tool in both diagnostics and therapeutic applications.
The SARS-CoV-2 virus has a spike (S) protein on its surface, which is crucial for the virus’s ability to enter human cells. This spike protein is divided into two subunits: S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which specifically binds to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells . This binding is the first step in the viral entry process.
The Recombinant Anti-Human SARS-CoV-2 IgG Spike S1, Monoclonal antibody is designed to target this S1 subunit. By binding to the S1 subunit, the antibody can block the interaction between the virus and the ACE2 receptor, thereby preventing the virus from entering human cells .
Recombinant monoclonal antibodies are produced using recombinant DNA technology. This involves inserting the gene encoding the antibody into a suitable host cell, such as a Chinese hamster ovary (CHO) cell line. The host cells then produce the antibody, which is subsequently purified using techniques such as protein A affinity chromatography .
- Diagnostics: These antibodies are used in various diagnostic assays, including ELISA (enzyme-linked immunosorbent assay) and Western blotting, to detect the presence of the SARS-CoV-2 virus in patient samples .
- Therapeutics: Monoclonal antibodies can be used as a form of passive immunization. By administering these antibodies to patients, it is possible to provide immediate protection against the virus. This is particularly useful for individuals who are at high risk of severe disease .
- Research: These antibodies are also valuable tools in research, helping scientists to study the virus’s structure and function, as well as to develop new vaccines and treatments .
- Specificity: Monoclonal antibodies are highly specific to their target antigen, which reduces the likelihood of cross-reactivity with other proteins.
- Consistency: Recombinant production ensures that each batch of antibodies is identical, providing consistent results in diagnostic and therapeutic applications.
- Scalability: The use of recombinant DNA technology allows for large-scale production of these antibodies, making them readily available for widespread use .
